20 and without clinical diagnosis of dementia or Alzheimer's disease). Individuals who are currently receiving antihypertensives are eligible to participate if the participants and the primary care providers are willing to taper their antihypertensives. Participants undergo cognitive assessment, measurements of cerebral blood flow using Transcranial Doppler, and central endothelial function by measuring changes in cerebral blood flow in response to changes in end tidal carbon dioxide at baseline (off antihypertensives), 6, and 12 months. Our outcomes are change in cognitive function score (executive and memory), cerebral blood flow, and carbon dioxide cerebral vasoreactivity. The AVEC trial is the first study to explore impact of antihypertensives in those who are showing early evidence of cognitive difficulties that did not reach the threshold of dementia. Success of this trial will offer new therapeutic application of antihypertensives that inhibit the renin angiotensin system and new insights in the role of this system in aging. Clinicaltrials.gov NCT00605072"/> Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Geriatrics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition

BMC Geriatrics20099:48

https://doi.org/10.1186/1471-2318-9-48

Received: 24 September 2009

Accepted: 18 November 2009

Published: 18 November 2009

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
24 Sep 2009 Submitted Original manuscript
7 Oct 2009 Author responded Author comments - Ihab Hajjar
Resubmission - Version 2
7 Oct 2009 Submitted Manuscript version 2
21 Oct 2009 Author responded Author comments - Ihab Hajjar
Resubmission - Version 3
21 Oct 2009 Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
Resubmission - Version 6
Submitted Manuscript version 6
5 Nov 2009 Author responded Author comments - Ihab Hajjar
Resubmission - Version 7
5 Nov 2009 Submitted Manuscript version 7
Resubmission - Version 8
Submitted Manuscript version 8
12 Nov 2009 Author responded Author comments - Ihab Hajjar
Resubmission - Version 9
12 Nov 2009 Submitted Manuscript version 9
Publishing
18 Nov 2009 Editorially accepted
18 Nov 2009 Article published 10.1186/1471-2318-9-48

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Harvard Medical School
(2)
Institue for Aging Research, Hebrew SeniorLife
(3)
Division of Gerontology, Beth Israel Deaconess Medical Centre
(4)
GRECC VA Boston Healthcare

Advertisement